Silvia Corcione

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8593401/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Vaccine development and technology for SARSâ€CoVâ€2: Current insight. Journal of Medical Virology, 2022, 94, 878-896.	5.0	8
2	A Response to: Letter to the Editor Regarding Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2022, 11, 635-638.	4.0	1
3	Beta Lactams Plus Daptomycin Combination Therapy for Infective Endocarditis: An Italian National Survey (BADAS). Antibiotics, 2022, 11, 56.	3.7	2
4	Risk Factors for Intra-Abdominal Candidiasis in Intensive Care Units: Results from EUCANDICU Study. Infectious Diseases and Therapy, 2022, 11, 827-840.	4.0	13
5	Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales. Clinical Microbiology and Infection, 2022, 28, 1290.e1-1290.e4.	6.0	7
6	Liver involvement and mortality in COVID-19: A retrospective analysis from the CORACLE study group. Infezioni in Medicina, 2022, 30, 80-85.	1.1	1
7	Temocillin: Applications in Antimicrobial Stewardship as a Potential Carbapenem-Sparing Antibiotic. Antibiotics, 2022, 11, 493.	3.7	8
8	Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/Ĩ²-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians. Pharmaceuticals, 2022, 15, 463.	3.8	13
9	Emerging Treatment Options for Acute Bacterial Skin and Skin Structure Infections and Bloodstream Infections Caused by Staphylococcus aureus: A Comprehensive Review of the Evidence. Infection and Drug Resistance, 2022, Volume 15, 2137-2157.	2.7	7
10	Effectiveness of an Active and Continuous Surveillance Program for Intensive Care Units Infections Based on the EPIC III (Extended Prevalence of Infection in Intensive Care) Approach. Journal of Clinical Medicine, 2022, 11, 2482.	2.4	2
11	An Observational Study of MDR Hospital-Acquired Infections and Antibiotic Use during COVID-19 Pandemic: A Call for Antimicrobial Stewardship Programs. Antibiotics, 2022, 11, 695.	3.7	19
12	Bloodstream Infections Caused by Carbapenem-Resistant Pathogens in Intensive Care Units: Risk Factors Analysis and Proposal of a Prognostic Score. Pathogens, 2022, 11, 718.	2.8	11
13	Bacterial and Viral Infections in Liver Transplantation: New Insights from Clinical and Surgical Perspectives. Biomedicines, 2022, 10, 1561.	3.2	3
14	Infective Endocarditis in People Who Inject Drugs: Report from the Italian Registry of Infective Endocarditis. Journal of Clinical Medicine, 2022, 11, 4082.	2.4	4
15	Daptomycin-based aminoglycoside-sparing therapy for streptococcal endocarditis: a retrospective multicenter study. Journal of Chemotherapy, 2021, 33, 435-439.	1.5	2
16	The "scar―of a pandemic: Cumulative incidence of COVIDâ€19 during the first trimester of pregnancy. Journal of Medical Virology, 2021, 93, 537-540.	5.0	50
17	Epidemiology, prevalence and risk factors for infections in burn patients: results from a regional burn centre's analysis. Journal of Chemotherapy, 2021, 33, 62-66.	1.5	11
18	Giardiasis reactivation during severe SARS-CoV-2 infection. Parasitology International, 2021, 80, 102241.	1.3	8

#	Article	IF	CITATIONS
19	Pulmonary Echinococcosis or Lung Hydatidosis: A Narrative Review. Surgical Infections, 2021, 22, 485-495.	1.4	17
20	Ozone therapy in COVID-19: A narrative review. Virus Research, 2021, 291, 198207.	2.2	44
21	Ceftobiprole Perspective: Current and Potential Future Indications. Antibiotics, 2021, 10, 170.	3.7	17
22	Ceftazidime-Avibactam Use for Klebsiella pneumoniae Carbapenemase–Producing <i>K. pneumoniae</i> Infections: A Retrospective Observational Multicenter Study. Clinical Infectious Diseases, 2021, 73, 1664-1676.	5.8	130
23	Incidence and Prognosis of Ventilator-Associated Pneumonia in Critically III Patients with COVID-19: A Multicenter Study. Journal of Clinical Medicine, 2021, 10, 555.	2.4	93
24	The Impact of Carbapenem Resistance on Mortality in Patients With Klebsiella Pneumoniae Bloodstream Infection: An Individual Patient Data Meta-Analysis of 1952 Patients. Infectious Diseases and Therapy, 2021, 10, 541-558.	4.0	18
25	Personalized stewardship and interdisciplinarity: key elements of COVID-19. Microbes and Infection, 2021, 23, 104781.	1.9	0
26	Cost-Effectiveness Analysis of the Prophylactic Use of Ertapenem for the Prevention of Surgical Site Infections after Elective Colorectal Surgery. Antibiotics, 2021, 10, 259.	3.7	0
27	COVID-19 pneumonia: do notÂleave the corticosteroids behind!. Future Microbiology, 2021, 16, 317-322.	2.0	7
28	Putative invasive pulmonary aspergillosis within medical wards and intensive care units: a 4-year retrospective, observational, single-centre study. Internal and Emergency Medicine, 2021, 16, 1619-1627.	2.0	10
29	Longitudinal analysis of antibody response following SARS-CoV-2 infection in pregnancy: From the first trimester to delivery. Journal of Reproductive Immunology, 2021, 144, 103285.	1.9	18
30	Novel Cephalosporins in Septic Subjects and Severe Infections: Present Findings and Future Perspective. Frontiers in Medicine, 2021, 8, 617378.	2.6	11
31	Realâ€life study on the pharmacokinetic of remdesivir in ICU patients admitted for severe COVIDâ€19 pneumonia. British Journal of Clinical Pharmacology, 2021, 87, 4861-4867.	2.4	7
32	Antiviral treatment selection for SARS-CoV-2 pneumonia. Expert Review of Respiratory Medicine, 2021, 15, 985-992.	2.5	4
33	Risk Factors for Mortality in COVID-19 Hospitalized Patients in Piedmont, Italy: Results from the Multicenter, Regional, CORACLE Registry. Journal of Clinical Medicine, 2021, 10, 1951.	2.4	17
34	Oral neomycin and bacitracin are effective in preventing surgical site infections in elective colorectal surgery: a multicentre, randomized, parallel, single-blinded trial (COLORAL-1). Updates in Surgery, 2021, 73, 1775-1786.	2.0	6
35	Use of exogenous pulmonary surfactant in acute respiratory distress syndrome (ARDS): Role in SARS-CoV-2-related lung injury. Respiratory Physiology and Neurobiology, 2021, 288, 103645.	1.6	23
36	Antibiotic De-escalation Experience in the Setting of Emergency Department: A Retrospective, Observational Study. Journal of Clinical Medicine, 2021, 10, 3285.	2.4	4

#	Article	IF	CITATIONS
37	Clinical Management of Adult Patients with COVID-19 Outside Intensive Care Units: Guidelines from the Italian Society of Anti-Infective Therapy (SITA) and the Italian Society of Pulmonology (SIP). Infectious Diseases and Therapy, 2021, 10, 1837-1885.	4.0	28
38	Non-fermentative gram-negative bloodstream infection in northern Italy: a multicenter cohort study. BMC Infectious Diseases, 2021, 21, 806.	2.9	11
39	Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context. Biomedicines, 2021, 9, 1288.	3.2	6
40	Monoclonal antibodies for the treatment of COVID-19 patients: An umbrella to overcome the storm?. International Immunopharmacology, 2021, 101, 108200.	3.8	20
41	Observed concentrations of amikacin and gentamycin in the setting of burn patients with gram-negative bacterial infections: Preliminary data from a prospective study. Therapie, 2021, 76, 409-414.	1.0	2
42	Infection Control in the Era of COVID-19: A Narrative Review. Antibiotics, 2021, 10, 1244.	3.7	15
43	Carbapenemase-Producing Klebsiella pneumoniae Colonization and Infection in Solid Organ Transplant Recipients: A Single-Center, Retrospective Study. Microorganisms, 2021, 9, 2272.	3.6	8
44	Exogenous Fungal Endophthalmitis: Clues to Aspergillus Aetiology with a Pharmacological Perspective. Microorganisms, 2021, 9, 74.	3.6	9
45	Management of Invasive Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: The Turin Experience. Frontiers in Cellular and Infection Microbiology, 2021, 11, 805514.	3.9	7
46	Use of colistin in adult patients: A cross-sectional study. Journal of Global Antimicrobial Resistance, 2020, 20, 43-49.	2.2	29
47	Pharmacokinetics of meropenem in burn patients with infections caused by Gram-negative bacteria: Are we getting close to the right treatment?. Journal of Global Antimicrobial Resistance, 2020, 20, 22-27.	2.2	7
48	Visceral leishmaniasis in a patient with active HBV/HDV co-infection. Journal of Infection and Public Health, 2020, 13, 306-308.	4.1	3
49	Ceftazidime-avibactam susceptible to resistant KPC-producing <i>Enterobacterales</i> bloodstream infections: an observational study. Journal of Chemotherapy, 2020, 32, 160-162.	1.5	12
50	Inpatient Mortality According to Level of Respiratory Support Received for Severe Acute Respiratory Syndrome Coronavirus 2 (Coronavirus Disease 2019) Infection: A Prospective Multicenter Study. , 2020, 2, e0220.		2
51	New cephalosporins for the treatment of pneumonia in internal medicine wards. Journal of Thoracic Disease, 2020, 12, 3747-3763.	1.4	14
52	Risk Factors for Candidemia After Open Heart Surgery: Results From a Multicenter Case–Control Study. Open Forum Infectious Diseases, 2020, 7, ofaa233.	0.9	7
53	COVID-19: in the uncertainty, do not try this at home. Internal and Emergency Medicine, 2020, 15, 1599-1600.	2.0	2
54	Fulminant septic shock due to Edwardsiella tarda infection associated with multiple liver abscesses: a case report and review of theÂliterature. Journal of Medical Case Reports, 2020, 14, 144.	0.8	8

#	Article	IF	CITATIONS
55	Microbiome in the setting of burn patients: implications for infections and clinical outcomes. Burns and Trauma, 2020, 8, tkaa033.	4.9	18
56	The Management of Hematologic Patients with Bloodstream Infections Due to Multi-Drug Resistant Bacteria: Where Do We Stand? From Antibacterial Prophylaxis to the Treatment of Septic Shock. Hemato, 2020, 1, 60-76.	0.6	3
57	COVID â€19: where have the lymphocytes gone?. Internal Medicine Journal, 2020, 50, 1436-1437.	0.8	2
58	Outcome of COVIDâ€19 in liver transplant recipients: A preliminary report from Northwestern Italy. Transplant Infectious Disease, 2020, 22, e13353.	1.7	27
59	2019 novel coronavirus (2019-nCoV) outbreak: A new challenge. Journal of Global Antimicrobial Resistance, 2020, 21, 22-27.	2.2	232
60	Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales. Antibiotics, 2020, 9, 71.	3.7	68
61	Point prevalence data on antimicrobial usage in Italian acute-care hospitals: Evaluation and comparison of results from two national surveys (2011–2016). Infection Control and Hospital Epidemiology, 2020, 41, 579-584.	1.8	11
62	Acute wound infections management: the â€~Don'ts' from a multidisciplinary expert panel. Expert Review of Anti-Infective Therapy, 2020, 18, 231-240.	4.4	13
63	Efficacy of Ceftazidime-Avibactam Salvage Therapy in Patients With Infections Caused by <i>Klebsiella pneumoniae</i> Carbapenemase–producing <i>K. pneumoniae</i> . Clinical Infectious Diseases, 2019, 68, 355-364.	5.8	265
64	Surgical antimicrobial prophylaxis prescribing practices and impact on infection risk: Results from a multicenter surveillance study in Italy (2012-2017). American Journal of Infection Control, 2019, 47, 1426-1430.	2.3	10
65	Choosing wisely: what is the actual role of antimicrobial stewardship in Intensive Care Units?. Minerva Anestesiologica, 2019, 85, 71-82.	1.0	6
66	Real-life use of isavuconazole outside the hematological wards. European Journal of Internal Medicine, 2019, 70, e10-e12.	2.2	1
67	Enteropathogenetic nosocomial infections: predisposing clinical characteristics and risk of recurrent infections. Journal of Chemotherapy, 2019, 31, 394-400.	1.5	4
68	Bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii: Clinical features, therapy and outcome from a multicenter study. Journal of Infection, 2019, 79, 130-138.	3.3	67
69	Incidence and outcome of invasive candidiasis in intensive care units (ICUs) in Europe: results of the EUCANDICU project. Critical Care, 2019, 23, 219.	5.8	123
70	Current and emerging pharmacotherapy for the treatment of infections following open-heart surgery. Expert Opinion on Pharmacotherapy, 2019, 20, 751-772.	1.8	8
71	Skin and soft tissue infections after breast surgery. Current Opinion in Infectious Diseases, 2019, 32, 87-94.	3.1	4
72	Carbapenem-sparing strategy: carbapenemase, treatment, and stewardship. Current Opinion in Infectious Diseases, 2019, 32, 663-673.	3.1	40

#	Article	IF	CITATIONS
73	Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration–Time Curve of Linezolid for Different ABCB1 Genotypes. Therapeutic Drug Monitoring, 2019, 41, 254-255.	2.0	1
74	A Position Paper on IgM-Enriched Intravenous Immunoglobulin Adjunctive Therapy in Severe Acute Bacterial Infections: The TO-PIRO SCORE Proposal. New Microbiologica, 2019, 42, 176-180.	0.1	3
75	Acquisition of FKS2 mutation after echinocandin treatment of infective endocarditis by Candida glabrata. Infezioni in Medicina, 2019, 27, 328-331.	1.1	1
76	The optimal duration of treatment for skin and soft tissue infections and acute bacterial skin and skin structure infections. Current Opinion in Infectious Diseases, 2018, 31, 155-162.	3.1	10
77	Neurological disease may precede lymphadenopathies in Actinomyces europaeus infection. Journal of Infection and Public Health, 2018, 11, 592-593.	4.1	3
78	Response to: â€`Letter to the Editor: "Management of multidrug-resistant Pseudomonas aeruginosa in the Intensive Care Unit: state of the artâ€â€™. Expert Review of Anti-Infective Therapy, 2018, 16, 369-371.	4.4	1
79	Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents, 2018, 51, 244-248.	2.5	55
80	Epidemiology and risk factors for mortality in bloodstream infection by CP-Kp, ESBL-E, Candida and CDI: A single center retrospective study. European Journal of Internal Medicine, 2018, 48, 44-49.	2.2	14
81	First case of E. meningoseptica in Italy in a patient with necrotic hemorrhagic pancreatitis. Infection, 2018, 46, 123-125.	4.7	5
82	A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance. Therapeutic Drug Monitoring, 2018, 40, 602-609.	2.0	14
83	Staphylococcus aureus producing Panton-Valentine Leukocidin: an emerging problem in Italian ICUs. Minerva Anestesiologica, 2018, 84, 641-642.	1.0	0
84	A retrospective study of viral central nervous system infections: relationship amongst aetiology, clinical course and outcome. Infection, 2017, 45, 227-231.	4.7	19
85	Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration. International Journal of Antimicrobial Agents, 2017, 49, 784-785.	2.5	6
86	Previous bloodstream infections due to other pathogens as predictors of carbapenem-resistant Klebsiella pneumoniae bacteraemia in colonized patients: results from a retrospective multicentre study. European Journal of Clinical Microbiology and Infectious Diseases, 2017, 36, 663-669.	2.9	32
87	Liver transplantation with an uncommon full right hemiliver graft after hydatid cysts resection: Case report and review of the literature. Transplant Infectious Disease, 2017, 19, e12685.	1.7	1
88	Management of multidrug-resistant <i>Pseudomonas aeruginosa</i> in the intensive care unit: state of the art. Expert Review of Anti-Infective Therapy, 2017, 15, 861-871.	4.4	51
89	Pharmacokinetics of colistin methanesulfonate (CMS) in burn patients: TableÂ1 Journal of Antimicrobial Chemotherapy, 2017, 72, 319-321.	3.0	8
90	Antifungal Treatment Strategies in the ICU: Beyond Meta-analysis. Turkish Journal of Anaesthesiology and Reanimation, 2017, 44, 283-284.	0.8	4

#	Article	IF	CITATIONS
91	Appropriate Treatment of Invasive Candidiasis in ICU: Timing, Colonization Index, Candida Score & Biomarkers, Towards de-Escalation?. Turkish Journal of Anaesthesiology and Reanimation, 2017, 44, 279-282.	0.8	10
92	Pharmacogenomic influence on sepsis outcome in critically ill patients. Infezioni in Medicina, 2017, 25, 45-49.	1.1	4
93	Management of carbapenem-resistant K. pneumoniae in allogenic stem cell transplant recipients: the Turin bundle. New Microbiologica, 2017, 40, 143-145.	0.1	6
94	Recommendations for the management of pulmonary fungal infections in patients with rheumatoid arthritis. Clinical and Experimental Rheumatology, 2017, 35, 1018-1028.	0.8	8
95	Miliary pulmonary infection after BCG intravesical instillation: a rare, misdiagnosed and mistreated complication. Infezioni in Medicina, 2017, 25, 366-370.	1.1	4
96	The Gastrointestinal Microbiome and the Enteropathogenetic Syndromes. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
97	Antimicrobial Stewardship in a Long-Term Acute Care Hospital Using Offsite Electronic Medical Record Audit. Infection Control and Hospital Epidemiology, 2016, 37, 433-439.	1.8	34
98	Risk factors for mortality in patients with <i>Staphylococcus aureus</i> bloodstream infection. Journal of Chemotherapy, 2016, 28, 187-190.	1.5	10
99	Current Pharmacological Treatment of Pulmonary Aspergillosis. Clinical Pulmonary Medicine, 2015, 22, 205-214.	0.3	0
100	The Effect on Mortality of Fluconazole or Echinocandins Treatment in Candidemia in Internal Medicine Wards. PLoS ONE, 2015, 10, e0125149.	2.5	34
101	Effect of SNPs in human ABCB1 on daptomycin pharmacokinetics in Caucasian patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 307-308.	3.0	10
102	From ESKAPE to ESCAPE, From KPC to CCC. Clinical Infectious Diseases, 2015, 60, 1289-1290.	5.8	36
103	Start Smart With Antimicrobial Stewardship: Table 1 Clinical Infectious Diseases, 2015, 61, 1033-1034.	5.8	3
104	Clinical epidemiology in Italian Registry of Infective Endocarditis (RIEI): Focus on age, intravascular devices and enterococci. International Journal of Cardiology, 2015, 190, 151-156.	1.7	41
105	Infections caused by KPC-producing <i>Klebsiella pneumoniae</i> : differences in therapy and mortality in a multicentre study. Journal of Antimicrobial Chemotherapy, 2015, 70, 2133-2143.	3.0	434
106	Pharmacokinetics of high dosage of linezolid in two morbidly obese patients. Journal of Antimicrobial Chemotherapy, 2015, 70, 2417-2418.	3.0	12
107	Critical issues for <i>Klebsiella pneumoniae</i> KPC-carbapenemase producing <i>K. pneumoniae</i> infections: a critical agenda. Future Microbiology, 2015, 10, 283-294.	2.0	39
108	Epidemiology and Treatment of MDR Enterobacteriaceae. Current Treatment Options in Infectious Diseases, 2015, 7, 291-316.	1.9	13

#	Article	IF	CITATIONS
109	Pharmacokinetics of high dosage of linezolid in two morbidly obese patients—authors' response: Figure 1 Journal of Antimicrobial Chemotherapy, 2015, 70, 3169-3169.	3.0	0
110	A one-year survey of carbapenemase-producing Klebsiella pneumoniae in Italy: beyond the ICU. Clinical Microbiology and Infection, 2015, 21, e11-e13.	6.0	17
111	Current and future therapies for invasive aspergillosis. Pulmonary Pharmacology and Therapeutics, 2015, 32, 155-165.	2.6	16
112	Molecular Characterization of Toxigenic Clostridium difficile in a Northern Italian Hospital. Current Microbiology, 2015, 70, 154-155.	2.2	5
113	Re-defining tigecycline therapy. New Microbiologica, 2015, 38, 121-36.	0.1	18
114	Candidemia, and infections by Clostridium difficile and carbapenemase-producing Enterobacteriaceae: new enteropathogenetic opportunistic syndromes?. Infezioni in Medicina, 2015, 23, 105-16.	1.1	14
115	Wound botulism after traumatic open fracture in Italy. Infezioni in Medicina, 2015, 23, 280-2.	1.1	1
116	A 30-years Review on Pharmacokinetics of Antibiotics: Is the Right Time for Pharmacogenetics?. Current Drug Metabolism, 2014, 15, 581-598.	1.2	52
117	Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: a prospective observational multicentre study. Clinical Microbiology and Infection, 2014, 20, 1357-1362.	6.0	182
118	Healthcare-Associated Klebsiella pneumoniae carbapenemase Producing K. pneumoniae Bloodstream Infection: The Time Has Come. Clinical Infectious Diseases, 2014, 59, 321-322.	5.8	8
119	Predictive Models for Identification of Hospitalized Patients Harboring KPC-Producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 2014, 58, 3514-3520.	3.2	75
120	Molecular epidemiology of methicillin-resistant S. aureus in the ICU setting. Intensive Care Medicine, 2014, 40, 759-760.	8.2	3
121	Extra Corporeal Membrane Oxygenation (ECMO) in three HIV-positive patients with acute respiratory distress syndrome. BMC Anesthesiology, 2014, 14, 37.	1.8	27
122	Anidulafungin versus fluconazole: clinical focus on IDSA and ESCMID guidelines. Infezioni in Medicina, 2014, 22, 107-11.	1.1	3
123	High rate of respiratory MDR gram-negative bacteria in H1N1-ARDS treated with ECMO. Intensive Care Medicine, 2013, 39, 1880-1881.	8.2	7
124	Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. International Journal of Antimicrobial Agents, 2013, 41, 590-591.	2.5	43
125	Development and validation of a new UPLC-PDA method to quantify linezolid in plasma and in dried plasma spots. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2013, 936, 42-47.	2.3	33
126	Mortality in patients with early- or late-onset candidaemia. Journal of Antimicrobial Chemotherapy, 2013, 68, 927-935.	3.0	37

#	Article	IF	CITATIONS
127	Pharmacokinetics of anidulafungin in two critically ill patients with septic shock undergoing CVVH. Journal of Chemotherapy, 2013, 25, 376-378.	1.5	11
128	Anidulafungin for Candida glabrata Infective Endocarditis. Antimicrobial Agents and Chemotherapy, 2012, 56, 4552-4553.	3.2	18